Payment overview · 2025
General Payments
$108.00
5 reported records · 5 companies
Healthcare provider profile · identity verified
David Olmstead, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ORLAND PARK, IL · NPI 1982610861
Verified facts
What the public records show
CMS Open Payments records show David Olmstead, M.D. received $108.00 in general payments during 2025 across 5 reported records.
Phadia US Inc. accounted for 25.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phadia US Inc. | Unresolved — no canonical attribution shown | $27.51 | 25.5% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $23.14 | 21.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.81 | 21.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.37 | 17.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.17 | 15.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $108.00 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $27.51 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.81 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $22.81 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.81 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 160 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
160 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1065 | 296 |
| Amlodipine Besylate | Amlodipine Besylate | 1003 | 275 |
| Losartan Potassium | Losartan Potassium | 510 | 144 |
| Lisinopril | Lisinopril | 486 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 483 | 124 |
| Metformin Hcl | Metformin Hcl | 382 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 325 | 88 |
| Simvastatin | Simvastatin | 247 | 60 |
| Omeprazole | Omeprazole | 245 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 234 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 231 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 230 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 222 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 209 | 50 |
| Furosemide | Furosemide | 199 | 58 |
| Eliquis | Apixaban | 189 | 47 |
| Gabapentin | Gabapentin | 187 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 186 | 35 |
| Metformin Hcl Er | Metformin Hcl | 164 | 43 |
| Allopurinol | Allopurinol | 162 | 45 |
| Sertraline Hcl | Sertraline Hcl | 162 | 44 |
| Jardiance | Empagliflozin | 160 | 43 |
| Alprazolam | Alprazolam | 145 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 41 |
| Warfarin Sodium | Warfarin Sodium | 133 | 27 |
| Irbesartan | Irbesartan | 131 | 29 |
| Finasteride | Finasteride | 129 | 35 |
| Mirtazapine | Mirtazapine | 119 | 25 |
| Potassium Chloride | Potassium Chloride | 116 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 52 |
| Alendronate Sodium | Alendronate Sodium | 110 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 27 |
| Valsartan | Valsartan | 107 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 35 |
| Atenolol | Atenolol | 101 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 97 | 24 |
| Carvedilol | Carvedilol | 85 | 21 |
| Glipizide | Glipizide | 83 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 27 |
| Donepezil Hcl | Donepezil Hcl | 81 | 23 |
| Spironolactone | Spironolactone | 79 | 25 |
| Tramadol Hcl | Tramadol Hcl | 79 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 22 |
| Synthroid | Levothyroxine Sodium | 76 | 17 |
| Azithromycin | Azithromycin | 71 | 54 |
| Bupropion Xl | Bupropion Hcl | 71 | 15 |
| Memantine Hcl | Memantine Hcl | 71 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 71 | 20 |
| Chlorthalidone | Chlorthalidone | 70 | 21 |
| Buspirone Hcl | Buspirone Hcl | 67 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 65 | 20 |
| Lorazepam | Lorazepam | 64 | 15 |
| Lovastatin | Lovastatin | 63 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | 19 |
| Meloxicam | Meloxicam | 62 | 19 |
| Montelukast Sodium | Montelukast Sodium | 62 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 18 |
| Glimepiride | Glimepiride | 54 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | suppressed |
| Glipizide Er | Glipizide | 52 | 12 |
| Januvia | Sitagliptin Phosphate | 52 | 15 |
| Famotidine | Famotidine | 50 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 49 | 16 |
| Ezetimibe | Ezetimibe | 49 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Indapamide | Indapamide | 46 | 13 |
| Lansoprazole | Lansoprazole | 46 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | 12 |
| Ibuprofen | Ibuprofen | 45 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 44 | 11 |
| Nifedipine Er | Nifedipine | 44 | suppressed |
| Digoxin | Digoxin | 43 | suppressed |
| Ozempic | Semaglutide | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 15 |
| Verapamil Er | Verapamil Hcl | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 11 |
| Ramipril | Ramipril | 39 | suppressed |
| Prednisone | Prednisone | 38 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 25 |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Repaglinide | Repaglinide | 31 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 26 |
| Methimazole | Methimazole | 30 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 30 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 29 | 25 |
| Celecoxib | Celecoxib | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Lactulose | Lactulose | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 11 |
| Amoxicillin | Amoxicillin | 22 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 13 |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Nystatin | Nystatin | 18 | 12 |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Felodipine Er | Felodipine | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Dutasteride | Dutasteride | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $108.00 · 5 records | Phadia US Inc. | AREXVY, BEXSERO, EVENITY, ImmunoCAP, JARDIANCE, SAPIEN 3 Ultra RESILIA, SHINGRIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error